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Introduction
Good glycaemic control remains the cornerstone of
diabetes management despite recent scepticism about
tight glucose control strategies and concerns regard-
ing safety of highly intensive treatment in the
ACCORD study (1). Recent publications, including
our ‘Updated Recommendations from the Global
Partnership for Effective Diabetes Management’ (2),
continue to emphasise the essential role of good
glycaemic control in reducing the risk of diabetes
complications, although attempts to achieve glycae-
mic targets should always ensure patient safety. Some
individuals may be unsuited to a particularly aggressive
glucose-lowering regimen, for example, as illustrated
in ACCORD, where all-cause mortality, risk of hypo-
glycaemia and weight gain were increased in patients
exposed to this approach. Indeed, the treatment
strategy adopted in this trial cannot be used as a
benchmark for achieving optimal glycaemic control.
Ensuring good glycaemic control remains the most
effective therapeutic manoeuvre to reduce the risk of
development and⁄or progression of microvascular
disease. In contrast, the impact on macrovascular
complications is still a matter of debate. In the most
recent outcome studies, ACCORD, ADVANCE and
VADT (1,3,4), lowering HbA1c below 7% was not
associated with any signiﬁcant reduction in cardio-
vascular (CV) mortality. However, these results
require further critical appraisal. For example, the
overall CV mortality was much lower than the one
initially used to calculate the sample power of these
studies. Such an unexpectedly low mortality rate
most likely reﬂects the substantial changes in type 2
diabetes management over the past 10 years that
have incorporated multifactorial treatment strategies.
These include extensive use of statins, newer and
more effective agents for hypertension, increased use
of aspirin and smoking cessation programmes. With
such a comprehensive approach to patient care, it is
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doi: 10.1111/j.1742-1241.2009.02227.x 295more difﬁcult to demonstrate a signiﬁcant risk
reduction that can be assigned to glucose lowering
alone.
Another possible reason for these observations
may be that the study duration of ACCORD,
ADVANCE and VADT was too short to show a
signiﬁcant effect of intensive glucose control on
macrovascular complications. In contrast, in the
10-year UKPDS follow-up, relative risk reductions
for myocardial infarction (MI) and all-cause mor-
tality were signiﬁcantly lower in patients who
initially received intensive treatment compared with
those in the conventional treatment arm. More-
over, the initial beneﬁt in terms of microvascular
complications observed at the end of the interven-
tion trial remained unaltered at follow-up. There
was, however, quite a difference between the
patients enrolled in the UKPDS compared with
those in the ACCORD, ADVANCE and VADT tri-
als: newly diagnosed patients with no prior CV
events in the former, subjects with long-standing
disease and a high prevalence of microvascular and
macrovascular complications in the latter.
When all the large, long-term, prospective rando-
mised controlled clinical trials (UKPDS, PROactive,
ADVANCE, VADT and ACCORD) are included in a
meta-analysis, blood glucose lowering appears to be
associated with reduction of incident CV events (5).
Overall, a 0.9% reduction in HbA1c with intensive
therapy was associated with signiﬁcant reductions of
17% in non-fatal MI [odds ratio (OR): 0.83, 95%
conﬁdence interval (CI): 0.75–0.93] and 15% in cor-
onary heart disease (OR: 0.85, 95% CI: 0.77–0.93) vs.
conventional therapy (5). In a meta-regression analy-
sis, higher body mass index (BMI), duration of dia-
betes and incidence of severe hypoglycaemia were
associated with greater risk of CV death in intensive
treatment groups (6).
Altogether, these results support the need for
appropriate individualisation of glycaemic targets
and of the means to achieve these targets. Several
factors can be taken into consideration when tailor-
ing treatment including duration of diabetes, stage of
disease, life expectancy, risk of hypoglycaemia and
risk factors for CV disease (CVD). It should also be
noted that even apparently acceptable levels of HbA1c
can disguise wide daily ﬂuctuations in plasma glu-
cose that require control. Although these consider-
ations may sound relatively straightforward,
confusion exists in the healthcare community regard-
ing how this information can be translated into clini-
cal practice.
The primary goal of the Global Partnership for
Effective Diabetes Management is the provision of
practical guidance to improve patient outcomes in
diabetes. Our recommendations (2) have been
updated after publication of the most recent out-
come trials to incorporate a range for target HbA1c
(6.5–7%) to provide ﬂexibility to suit different
patient populations (2). In this article, we aim to
build on this by providing more explicit advice to
support healthcare professionals in appropriately
tailoring type 2 diabetes treatment. This includes:
(i) identiﬁcation of patient groups requiring special
consideration, including newly diagnosed individu-
als with type 2 diabetes but no complications
(overweight or obese adults, lean adults and chil-
dren), individuals with a history of inadequate
glycaemic control (no complications or history of
CVD) and individuals at risk of hypoglycaemia;
and (ii) provision of practical guidance speciﬁc to
each group.
Note that, given the existence of considerable
national and regional differences in the availability of
therapeutic options, recommendations concerning
the use of particular antidiabetic agents have been
avoided. Other regional differences, e.g. variations in
phenotype and genotype, should also be acknowl-
edged. In addition, we have not included individuals
with good glycaemic control as a separate popula-
tion. For these patients, the guidance is to maintain
the same regimen to keep patients at target and to
react quickly if HbA1c starts to rise, e.g. by timely
introduction of combination therapy or insulin as
appropriate.
Newly diagnosed individuals with type
2 diabetes, but no complications
Overweight or obese adults
Deﬁnition of patient type: HbA1c > 6.5%, BMI > 25
kg⁄m
2, typically > 30 years of age, diagnosis before
emergence of complications, mild symptoms or
asymptomatic, no associated comorbidities, e.g.
hypertension, dyslipidaemia.
As reviewed in previous Global Partnership publi-
cations (2,7–9), early and effective intervention to
improve glycaemic control is likely to confer the
greatest beneﬁts. Achieving such a goal, however,
requires a proactive approach including deﬁnition of
target HbA1c and prompt reaction at the ﬁrst sign of
any deviation from the target. This is in contrast
with the traditional stepwise approach to type 2 dia-
betes management, which often leads to signiﬁcant
delays in both achieving and maintaining glycaemic
goals and may result in long periods of hyperglyca-
emia. This approach is unacceptable given the evi-
dence that even short periods of hyperglycaemia
increase the risk of microvascular and macrovascular
complications (7).
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results from the follow-up to large-scale outcome
studies in both type 1 and type 2 diabetes, which
have led to the proposal of a metabolic memory or
metabolic legacy effect (10–14). The available evi-
dence suggests that early, strict glycaemic control
may confer protection against, or delay, the serious
long-term complications of the condition. For exam-
ple, during 8-year follow-up of the DCCT⁄EDIC
study in type 1 diabetes, earlier improvements in gly-
caemic control resulted in continued microvascular
beneﬁts as well as the emergence of macrovascular
risk reduction over time (11–14). Similarly, during
10 years’ follow-up of type 2 diabetes patients in the
UKPDS, a continued reduction in microvascular risk
as well as emergent reductions in the risk of MI and
death from any cause was observed with intensive vs.
conventional therapy (10). This was seen despite an
early convergence of HbA1c levels between the
groups. Potential mechanisms to explain the molecu-
lar basis for metabolic memory include increased
formation of cellular reactive species and advanced
glycation end products in response to chronic hyper-
glycaemia, resulting in the activation of pathways
involved in the pathogenesis of diabetes-related com-
plications (15,16).
Intervention later in the course of the disease pro-
vides less opportunity to inﬂuence the development
and⁄or progression of complications in patients with
long-standing diabetes. This is demonstrated by data
from ACCORD, in which subgroup analyses of the
intensively controlled group indicated a signiﬁcant
reduction in the primary CV end-point in
individuals with HbA1c £ 8% at baseline or those
who had not had a CV event before randomisation
(1). Further evidence comes from the meta-regres-
sion analysis of the outcome trials clearly indicating
that the earlier the intensive treatment, the larger the
risk reduction of CVD (6). The same analysis sug-
gests that the magnitude of the risk reduction
decreases in individuals with longer disease duration
with an increase in CVD risk in those with long-
standing diabetes (17).
All this can be readily appreciated by considering
Figure 1, which illustrates the drawbacks of late
intervention by hypothetically reconstructing the
natural history of patients recruited into
the VADT. Patients with poor glycaemic control
(HbA1c 9.4%) and long-standing diabetes (11.4
years) were recruited in the study. The solid line
represents changes in HbA1c over time in the
VADT (18). After entry into the VADT intensive
treatment arm, HbA1c decreased rapidly and was
subsequently maintained close to target levels.
However, although diabetes progression up to this
point remains unknown, it can be tentatively
reconstructed based on data from the UKPDS as a
case study. Thus, the upper broken line in Figure 1
represents the time course of HbA1c estimated on
the basis of the average glucose proﬁle observed in
the UKPDS (19), while the lower broken line rep-
resents the ideal time course of glycaemic control.
The difference between the ideal and the actual
time course of glycaemic control represents a time
period that must have had a negative effect on
subsequent tight glycaemic control. Clearly, reduc-
ing hyperglycaemia as early as possible is likely to
reduce risk of complications.
Figure 1 Estimated glycaemic legacy of patients recruited in VADT. Reproduced with kind permission of Springer Science
and Business Media from Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009;
52: 1219-26.
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overweight or obese adults
Current recommendations for this and other groups
of patients are summarised in Table 1. The points of
particular importance for this type of patient follow.
• Newly diagnosed type 2 diabetes patients with
no evidence of complications should aim for the
bottom of the HbA1c target range (6.5–7%), i.e.
HbA1c as close to normal as can safely be achieved
without causing hypoglycaemia or marked weight
gain. HbA1c should be monitored every 3 months,
and initiating combination therapy should be
considered if target HbA1c is not reached within
3 months.
• Note the need to aim for normal HbA1c wherever
appropriate, even in patients with modest hyper-
glycaemia (HbA1c < 7.5%).
• In patients with mild to moderate hyperglycaemia
(HbA1c < 7.5%), consider agents that are not associ-
ated with an increased risk of hypoglycaemia and
that address the underlying pathophysiology of dia-
betes, including the treatment of b-cell dysfunction
and insulin resistance.
• In patients with HbA1c > 9%, consider initiating
combination therapy or insulin.
• For overweight or obese patients, as for all subjects
with type 2 diabetes, diet and exercise should be con-
tinually reiterated.
• As overweight and obese patients are at increased
risk of CVD, particular attention should be given to
manage all CV risk factors.
Lean adults
Deﬁnition of patient type: HbA1c > 6.5%, BMI < 25
kg⁄m
2, typically > 30 years of age, diagnosis before
emergence of complications, mild symptoms or
asymptomatic, no associated comorbidities, e.g.
hypertension, dyslipidaemia.
Although the majority of individuals with type 2
diabetes are overweight or obese, a substantial
number are considered lean by traditional standards,
particularly in Asian countries (20). Notably, the
proportion of type 2 diabetes cases attributable to
obesity varies greatly across the world, from almost
90% in North America to < 40% in Southeast Asia
(20). There is some evidence that the percentage of
body fat for a given BMI is higher amongst certain
Asian populations, which has led to the introduction
of lower waist circumference and BMI thresholds for
deﬁning overweight⁄obese patients in some coun-
tries, e.g. Japan and China (20).
A major consideration in lean patients is the
degree of b-cell dysfunction, and this may affect the
choice of agent. b-cell dysfunction may be more
marked in lean patients compared with over-
weight⁄obese individuals, and this is particularly true
in some non-Western populations. For example, in a
study of Korean type 2 diabetes patients with
BMI < 25 kg⁄m
2, only 24% was found to be insulin
resistant (20). However, pathophysiological heteroge-
neity is also often increased in lean patients, which
presents a particular therapeutic challenge. Given this
heterogeneity and the practical difﬁculties of deter-
mining the exact degree of insulin resistance and
insulin deﬁciency, a rational approach may be to
ensure that both defects are addressed in the thera-
peutic regimen (20). Also, as ethnic and phenotypic
variations across regions of the world appear to pro-
vide different contributions to the pathophysiology
of the condition, it is important that this diversity is
reﬂected in the treatment approach.
Lean patients may have a different proﬁle in
terms of susceptibility to macrovascular disease
compared with overweight or obese individuals,
with fewer risk factors for CVD and a lower risk
of macrovascular vs. microvascular complications
(20,21). Hence, the primary focus for lean patients
is likely to be glycaemic control, while in over-
weight or obese patients multifactorial intervention
to address CV risk factors such as dyslipidaemia
and hypertension as well as hyperglycaemia may be
more urgent (20).
Practicalguidance fornewly diagnosed lean adults
• Newly diagnosed type 2 diabetes patients with no
evidence of complications should aim for the lower
end of the HbA1c target range (6.5–7%), i.e. HbA1c
as close to normal as can safely be achieved without
causing hypoglycaemia. HbA1c should be monitored
every 3 months and initiating combination therapy
should be considered if target HbA1c is not reached
within 3 months.
• Note the need to aim for normal HbA1c wherever
appropriate, even in patients with modest hyper-
glycaemia (HbA1c < 7.5%).
• Ideally, use agents that are not associated with an
increased risk of hypoglycaemia.
• In patients with HbA1c > 9%, consider initiating
combination therapy or insulin.
• Given the increased likelihood of b-cell dysfunc-
tion in newly diagnosed lean type 2 diabetes patients,
there may be a particular need for earlier therapy
(including early use of combination therapy) in this
group, including agents that support b-cell function
wherever appropriate.
• Although this group has a lower risk of CVD com-
pared with overweight or obese patients, individuals
should still be educated on the importance of
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with its associated risk of CV complications.
• Be aware that latent autoimmune diabetes in
adults (LADA), which constitutes around 10% of all
diagnosed type 2 diabetes patients (20), may be more
prevalent in lean patients. Therefore, it may be advis-
able wherever possible to test for islet autoantibodies,
such as antibodies to glutamic acid decarboxylase, if
LADA is suspected.
Children
Although type 1 diabetes is traditionally more com-
mon in children and adolescents, the burden of type
2 diabetes is increasing in young people with the
condition, with as many as 8–45% of new-onset pae-
diatric diabetes cases in the USA attributed to type 2
diabetes (22). The prevalence of type 2 diabetes is
also escalating in other regions, including Japan and
the UK (23,24). With this increasing prevalence
comes a pressing need to prevent or delay the devel-
opment of serious diabetes complications. In particu-
lar, onset of the disease at such an early age signals
the possibility of a signiﬁcant glycaemic legacy if dia-
betes is uncontrolled over a long time period. Note
that it is becoming increasingly difﬁcult to distin-
guish between type 1 and type 2 diabetes in children
given the signiﬁcant overlap between presenting con-
ditions. This has created a dilemma in terms of
selecting the most appropriate management strategy.
Moreover, as this phenomenon becomes increasingly
common, new treatment strategies will need to be
explored.
Involvement of a multidisciplinary approach to
patient care, with the affected individual and their
family taking a central role, is particularly impor-
tant for children with type 2 diabetes. Inclusion of
family members and friends can be particularly
beneﬁcial for individuals in terms of improving
both diabetes-related knowledge and glycaemic
control (25). Furthermore, many children with type
2 diabetes are overweight at diagnosis and most are
in families with other members who are at high
risk of diabetes, so lifestyle counselling and modiﬁ-
cation can involve the whole family (23). However,
not all cases are associated with overweight or
obesity, notably those in Asian and Oriental popu-
lations. As with all individuals with type 2 diabetes,
access to structured educational programmes is
essential (25).
Practical guidance for newly diagnosed
children
• Extra vigilance regarding long-term safety is para-
mount in children with type 2 diabetes.
• Given that individuals are facing decades of the
disease, aim for HbA1c targets in the normal range
without causing hypoglycaemia.
• Implement a multidisciplinary team approach to
diabetes care, with both the patient and their family
at the centre of the team. Involve the whole peer
group, including parents, carers and family, in edu-
cation regarding the importance of lifestyle and
counsel other family members, e.g. siblings, to
prevent development of diabetes.
Individuals with a history of
inadequate glycaemic control (lean
or obese)
No complications
Deﬁnition of patient type: Likely to be older than
newly diagnosed individuals with no complications
and with a longer duration of diabetes, e.g. inade-
quate glycaemic control (HbA1c > 7.5%) for
‡ 1 year, no associated comorbidities, e.g. hyperten-
sion, dyslipidaemia.
Reducing microvascular and macrovascular
complications represents a particular challenge in
individuals with more advanced disease and therefore
a high glycaemic burden. Before making treatment
decisions, it is necessary to consider the reasons for
an individual being inadequately controlled. Explana-
tions may include poor adherence, lack of awareness
of the beneﬁts of good glycaemic control, conserva-
tive or delayed use of combination therapy or insulin
by physicians and lower levels of b-cell function in
these patients (7).
If patients have a history of inadequate glycaemic
control this will confer a bad glycaemic legacy, as
described above. In those patients who have no com-
plications to date, it is important to lower HbA1c lev-
els to near normal to reduce the risk of
complications, while balancing the beneﬁts of good
glycaemic control with patient safety.
Practical guidance for patients with a history
of inadequate glycaemic control but no
complications
• Target near-normal HbA1c in this group of
patients, but aim for a more gradual reduction in
HbA1c compared with newly diagnosed individuals.
• Reassess the potential reasons for inadequate
glycaemic control, such as overly conservative man-
agement (including delay in introducing combina-
tion therapy), inadequate adherence to antidiabetic
regimens and inappropriate choice of agents (e.g.
agents that do not address the underlying patho-
physiology).
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to motivate individuals with type 2 diabetes to
assume a more active role in managing their
condition.
History of CVD
Deﬁnition of patient type: Known history of CVD,
likely to have large pill burden and restrictions on
choice of therapy because of comorbidities.
Insight regarding this patient population is pro-
vided by individuals who participated in ACCORD,
ADVANCE and VADT. These patients had a history
of poor glycaemic control, e.g. long duration of dia-
betes (8–11 years duration at baseline), high baseline
HbA1c and a high prevalence of CVD (1,3,4) and
these individuals are considered to be at particularly
high risk. However, prevention or reduction of com-
plications should be balanced against the need to
ensure patient safety. A highly intensive regimen as
used in ACCORD, which included rapid dose escala-
tion and introduction of polypharmacotherapy if tar-
get HbA1c was not achieved, was associated with a
22% increase in all-cause mortality (1), but prelimin-
ary analyses suggest that it was not the individuals
with either the fastest or the greatest lowering of
blood glucose that incurred this mortality (26).
These results suggest that very intensive regimens
may be inappropriate for some patients with more
advanced diabetes, thus highlighting the need to tai-
lor treatment to the individual. For example, a recent
position statement from the American Diabetes Asso-
ciation, American College of Cardiology and Ameri-
can Heart Association on intensive glycaemic control
and the prevention of CV events identiﬁed particu-
larly high risk individuals as those with a very long
duration of diabetes, a known history of severe
hypoglycaemia, advanced atherosclerosis or advanced
age⁄frailty (27).
Patients with a history of CVD who do not
respond to aggressive glucose-lowering strategies
may be more susceptible to CV events, as observed
in ACCORD (26) and individualisation of treat-
ment as well as HbA1c targets is needed (1,4).
Further detail is provided in ‘Individuals at risk of
hypoglycaemia’.
Practical guidance for individuals with a history
of inadequate glycaemic control and CVD
• Guidance is as for patients with a history of inade-
quate glycaemic control but no complications, but
taking particular care to avoid hypoglycaemia in this
group of patients.
• Cardiovascular risk management should be intensi-
ﬁed in these individuals.
• It is also important to adopt less stringent glycae-
mic targets and aim for a more gradual reduction in
HbA1c.
• Be vigilant to contraindications and other limita-
tions concerning choice of agents, bearing in mind
the possibility of drug interactions in this patient
group.
Individuals at risk of hypoglycaemia
Deﬁnition of patient type: Individuals with previous
symptoms of hypoglycaemia, those with particularly
wide daily glucose ﬂuctuations and individuals such
as elderly people who often have impaired creatinine
clearance in addition to irregular lifestyles⁄eating
patterns leading to increased susceptibility to hypo-
glycaemia, especially when taking hypoglycaemic
agents such as insulin and sulphonylureas.
Some therapeutic regimens are associated with a
signiﬁcantly increased risk of hypoglycaemia in
patients with type 2 diabetes (1,3,4,19). In the
UKPDS, the annual rates of major hypoglycaemia
were 0.7% with conventional treatment, 1.0% with
chlorpropamide, 1.4% with glibenclamide and 1.8%
with insulin. This risk was much higher in ACCORD,
in which the frequency of severe hypoglycaemia
(participants with one or more episodes during the
study) was 16.2% with intensive therapy vs. 5.1%
with conventional treatment. In ADVANCE, the
frequency was 2.7% and 1.5% for intensive and con-
ventional control, respectively, and in VADT it was
21.2% and 9.9% (27). Note the lower incidence in
ADVANCE, which may reﬂect a more gradual reduc-
tion in HbA1c over time, although the deﬁnition of
severe hypoglycaemia did vary considerably between
studies. The impact of intensive glycaemic control is
also observed in a meta-analysis based on pooled data
from UKPDS, PROactive, ADVANCE, VADT and
ACCORD, with twice as many people in the intensive
control group (2.3%) having a severe hypoglycaemic
episode vs. the standard control group (1.2%) (5).
In both ACCORD and VADT, an association was
observed between severe hypoglycaemia and CV
events, although no cause and effect relationship
could be demonstrated (17). Hypoglycaemia may in
fact be a marker of other features that may be associ-
ated with increased mortality, e.g. non-adherence or
autonomic neuropathy, a strong risk factor for sud-
den death (17).
Other studies also demonstrate the risks associated
with hypoglycaemia. For example, in a retrospective
analysis, increased risk of mortality was observed in
patients with persistent in-hospital hypoglycaemia
following admission for acute MI (28).
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especially in older patients with type 2 diabetes and,
in particular, in those with previous CV events (17).
Targets should be individualised according to the
risk of hypoglycaemia, e.g. history of severe or fre-
quent hypoglycaemia, kidney function, age of patient
and previous CV events.
Practical guidance for individuals at risk of
hypoglycaemia
• Educate patients on how to be alert to the possi-
bility of hypoglycaemia, aiming to increase awareness
and responsiveness to symptoms of hypoglycaemia.
• Counsel particularly vulnerable patients such as
elderly people on the increased risk of hypoglycaemia
with irregular lifestyles⁄eating patterns and encourage
compliance to prescribed regimens.
• Emphasise the importance of regular self-monitor-
ing of glucose wherever appropriate.
Conclusions
Good glycaemic control continues to have an essen-
tial role in type 2 diabetes management. Our recently
updated ‘10 steps to get more type 2 diabetes
patients to goal’ (2) remains the blueprint in terms
of practical guidance for helping patients to achieve
and maintain their glycaemic targets. However, hav-
ing reviewed the evidence, we recognise that individ-
ualising targets and⁄or treatment according to
patient type is paramount. For example, while early
intervention is preferred wherever appropriate, cer-
tain high risk groups may not respond to overly
intensive glucose-lowering regimens such as that uti-
lised in ACCORD.
In this article, we have identiﬁed which patient
groups require special consideration and provided
practical guidance speciﬁc to each group. While
some of our recommendations apply across all
patient groups, others are particularly applicable for
certain patients or else require individualisation to
achieve the optimal risk:beneﬁt in terms of patient
outcomes, as summarised in Table 1. We hope that
by providing structured advice on how to tailor
treatment according to the individual, we are one
step closer in our quest for the best possible out-
comes for our type 2 diabetes patients.
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